These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 3608504)

  • 1. The investigator-sponsored IND in clinical trials.
    Haakenson C; Fye CL; Sather MR; Toussaint DJ
    Control Clin Trials; 1987 Jun; 8(2):101-9. PubMed ID: 3608504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding FDA regulatory requirements for investigational new drug applications for sponsor-investigators.
    Holbein ME
    J Investig Med; 2009 Aug; 57(6):688-94. PubMed ID: 19602987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine INDs: review of clinical holds.
    Miller DL; Ross JJ
    Vaccine; 2005 Jan; 23(9):1099-101. PubMed ID: 15629351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An FDA analysis of clinical hold deficiencies affecting investigational new drug applications for oncology products.
    Manning ML; Thompson MD; Saber H; Maher VE; Crich JZ; Leighton JK
    Regul Toxicol Pharmacol; 2020 Feb; 110():104511. PubMed ID: 31678263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Support for investigator-initiated clinical research involving investigational drugs or devices: the Clinical and Translational Science Award experience.
    Berro M; Burnett BK; Fromell GJ; Hartman KA; Rubinstein EP; Schuff KG; Speicher LA;
    Acad Med; 2011 Feb; 86(2):217-23. PubMed ID: 21169787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A program to provide regulatory support for investigator-initiated clinical research.
    Arbit HM; Paller MS
    Acad Med; 2006 Feb; 81(2):146-53. PubMed ID: 16436575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RU 486, the FDA and free enterprise.
    Buc NL
    Law Med Health Care; 1992; 20(3):224-5. PubMed ID: 1434765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New drug development by United States pharmaceutical firms with analyses of trends in the acquisition and origin of drug candidates, 1963-1979.
    Wardell WM; May MS; Trimble AG
    Clin Pharmacol Ther; 1982 Oct; 32(4):407-17. PubMed ID: 7116754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harvard Catalyst | The Clinical Translational Science Center IND/IDE Consult Service: providing an IND/IDE consult service in a decentralized network of academic healthcare centers.
    Kim MJ; Winkler SJ; Bierer BE; Wolf D
    Clin Transl Sci; 2014 Apr; 7(2):150-5. PubMed ID: 24455986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
    Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
    Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials.
    Perez R; Archdeacon P; Roach N; Goodwin R; Jarow J; Stuccio N; Forrest A
    Clin Trials; 2017 Jun; 14(3):225-233. PubMed ID: 28345368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HIV/AIDS vaccine researchers' orientation to the process of preparing a US FDA application for an investigational new drug (IND): what it is all about and how you start by preparing for your pre-IND meeting.
    Shapiro SZ
    Vaccine; 2002 Jan; 20(9-10):1261-80. PubMed ID: 11818145
    [No Abstract]   [Full Text] [Related]  

  • 13. An Analysis of Antibacterial Drug Development Trends in the United States, 1980-2019.
    Dheman N; Mahoney N; Cox EM; Farley JJ; Amini T; Lanthier ML
    Clin Infect Dis; 2021 Dec; 73(11):e4444-e4450. PubMed ID: 32584952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responsibilities of university investigators when conducting trials on investigational new animal drugs.
    Parrott JC
    J Anim Sci; 1987 Aug; 65(2):577-80. PubMed ID: 3624100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Building a drug development database: challenges in reliable data availability.
    Audibert C; Romine M; Caze A; Daniel G; Leff J; McClellan M
    Drug Dev Ind Pharm; 2017 Jan; 43(1):74-78. PubMed ID: 27494335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer.
    Bonomi P; Stuccio N; Delgra CJ; Chuk MK; Spira A; Deitz AC; Blumenthal GM; Ferris A; Gong Y; He J; Basu Roy U; Selig W
    Ther Innov Regul Sci; 2020 Sep; 54(5):1208-1214. PubMed ID: 32865803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legal and ethical obligations to conduct a clinical drug trial in Australia as an investigator initiated and sponsored study for an overseas pharmaceutical company.
    Beran RG
    Med Law; 2004; 23(4):913-24. PubMed ID: 15685926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of research: is it a drug trial or a supplement trial?
    Chen ST
    Fitoterapia; 2011 Jan; 82(1):14-6. PubMed ID: 21073930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold.
    Lapteva L; Pariser AR
    J Investig Med; 2016 Feb; 64(2):376-82. PubMed ID: 26911627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical delivery of cultured stem cells to human non-healing wounds: GMP facility development in an academic setting and FDA requirements for an IND and human testing.
    Yufit T; Carson P; Falanga V
    Curr Drug Deliv; 2014; 11(5):572-81. PubMed ID: 23517627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.